Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomised, Double-blind, Placebo-controlled Phase III Study, Evaluating the Effect of Dapagliflozin on Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Anthracycline-based Chemotherapy

NCT06304857 is registered in ClinicalTrials.gov with 4th Military Clinical Hospital with Polyclinic, Poland as lead sponsor.

NCT NCT06304857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06304857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomised, Double-blind, Placebo-controlled Phase III Study, Evaluating the Effect of Dapagliflozin on Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Anthracycline-based Chemotherapy
Lead sponsor
4th Military Clinical Hospital with Polyclinic, Poland
Phase
Phase 3
Overall status
Recruiting
Start date
April 15, 2024
Completion date
December 31, 2027
Enrollment
188 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, heart failure